Systemic administration of HDACi delayed or completely abrogated tumor development, whereas T cell-specific depletion of HDAC1 or HDAC2 or inactivation of the catalytic activity of HDAC1 significantly accelerated lymphomagenesis. Here, HDAC2 is linked to neoplasm.